Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | CHKA | P35790 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792006 | 0.77 | ALDH1A1 (0.46) | TSHRHSD17B10ALDH1A1TP53MEN1 | |
| SCHEMBL4523362 | 0.76 | CSNK2A2 (0.36) | CSNK2A2CSNK2BCSNK2A1TSHRHSD17B10 | |
| SCHEMBL8754565 | 0.76 | CHKA (0.37) | CSNK2A2CSNK2BCSNK2A1TSHRALDH1A1 | |
| Iodide SCHEMBL2551843 | 0.74 | CHKA (0.36) | CSNK2A2CSNK2BCSNK2A1ALDH1A1TP53 | |
| SCHEMBL17031439 | 0.73 | CSNK2A1 (0.34) | CSNK2A1AHR | |
| SCHEMBL8722744 | 0.71 | CHKA (0.34) | CSNK2A2CSNK2BCSNK2A1ALDH1A1TP53 | |
| Trifluoroacetic Acid SCHEMBL14672349 | 0.68 | PDK1 (0.36) | TSHRALDH1A1TP53CASP1SMN1; SMN2 | |
| SCHEMBL29780384 | 0.63 | TP53 (0.55) | TSHRHSD17B10ALDH1A1CYP3A4TDP1 | |
| SCHEMBL5863631 | 0.63 | TP53 (0.55) | TSHRHSD17B10ALDH1A1CYP3A4TDP1 | |
| SCHEMBL14227843 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230348419-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348419-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | RECQL, NQO1, BRD4 | CSNK2A2 1287/4885CSNK2B 1595/4885CSNK2A1 1171/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.